TARCEVA
Total Payments
$220,432
Transactions
12
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $168,070 | 5 | 0 |
| 2019 | $52,291 | 3 | 0 |
| 2018 | $71.04 | 4 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $220,361 | 8 | 100.0% |
| Food and Beverage | $71.04 | 4 | 0.0% |
Payments by Type
Research
$220,361
8 transactions
General
$71.04
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE II STUDY OF STEREOTACTIC RADIOSURGERY OR OTHER LOCAL ABLATION FOLLOWED BY ERLOTINIB FOR PATIENTS WITH EGFR MUTATION WHO HAVE PREVIOUSLY PROGRESSED ON AN EGFR-TKI | Astellas Pharma Global Development | $65,213 | 0 |
| GENOMIC LANDSCAPE OF EGFR MUTANT NSCLC PRIOR TO ERLOTINIB AND AT THE TIME OF DISEASE PROGRESSION FOLLOWING ERLOTINIB | Astellas Pharma Global Development | $42,291 | 0 |
| Genomic landscape of EGFR mutant NSCLC prior to erlotinib and at the time of disease progression following erlotinib | Astellas Pharma Global Development | $42,291 | 0 |
| A PHASE II TRIAL OF RAPID INITIATION OF FIRST-LINE ERLOTINIB FOR ADVANCED NSCLC USING GENOTYPING OF CELL-FREE PLASMA DNA | Astellas Pharma Global Development | $33,441 | 0 |
| PHASE-II-125 ANALYSIS OF EGFR MUTATION STATUS IN PATIENT PLASMA | Astellas Pharma Global Development | $27,124 | 0 |
| Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor EGFRTyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | Astellas Pharma Global Development | $10,000 | 0 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $220,361
- Astellas Pharma US Inc $71.04
Product Information
- Type Drug
- Total Payments $220,432
- Total Doctors 4
- Transactions 12
About TARCEVA
TARCEVA is a drug associated with $220,432 in payments to 4 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2020. In 2020, $168,070 was paid across 5 transactions to 0 doctors.
The most common payment nature for TARCEVA is "Unspecified" ($220,361, 100.0% of total).
TARCEVA is associated with 6 research studies, including "PHASE II STUDY OF STEREOTACTIC RADIOSURGERY OR OTHER LOCAL ABLATION FOLLOWED BY ERLOTINIB FOR PATIENTS WITH EGFR MUTATION WHO HAVE PREVIOUSLY PROGRESSED ON AN EGFR-TKI" ($65,213).